The development of biological medicines (made from living organisms of variable nature) and biosimilars(similar or equivalent version of a biologic) has had strong growth and impact in the pharmaceutical market in recent years. Currently, between 30 and 50% of new medicines authorized in Europe are biosimilars. Since the European Medicines Agency (EMA) authorized the commercialization of a biosimilar for the first time in 2006, the use of this type of medicine has been increasing progressively, with Oncology, HIV, AIB and Hepatitis C being the fields with greater penetration. And this rhythm will foreseeably continue in the coming years: Medicines for Europe It calculates that some 2020 new biosimilars will be put on the market by 50; what has to do with the expiration, in the coming years, of the patents of different biological medicines.
The impact of biological and biosimilar medicines on Industry and Health in general (among others, allowing patients to increase access to innovative treatments) is therefore already a reality.
In this context, Azierta proposes to analyze the interconnection between the Science and the world<strong>Training</strong> business, through the analysis of different success stories in the development of innovative and biosimilar products. As well as the impact that this new type of products already has on the pharmaceutical market.
For this, the Conference will be held “Science to Business. Success stories in the development of innovators and biosimilars” on May 24 in the Félix Serratosa Hall of the Barcelona Science Park (C/ Baldiri Reixac, 10 08028 Barcelona), in which we will have the participation of Angel Navarro, Executive President of Azierta, Susana Millan, Medical & RA Director of mAbxience, Cesar Miller, Medical Director and Clinical Operations of Oryzon and Chelo Tudela, Senior Preclinical & Clinical Regulatory Specialist at Azierta.